Publicaciones en las que colabora con Jesus M. Prieto Valtueña (28)

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. Identifying differentially expressed micrornas, target genes, and key pathways deregulated in patients with liver diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 19, pp. 1-16

2019

  1. The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells

    Cell Death and Disease, Vol. 10, Núm. 1

2018

  1. TMEM173 Alternative Spliced Isoforms Modulate Viral Replication through the STING Pathway

    ImmunoHorizons, Vol. 2, Núm. 11, pp. 363-376

2017

  1. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

  2. X-box Binding Protein 1 Regulates Unfolded Protein, Acute-Phase, and DNA Damage Responses During Regeneration of Mouse Liver

    Gastroenterology, Vol. 152, Núm. 5, pp. 1203-1216.e15

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Insulin-like growth factor I (IGF-I) expressed from an AAV1 vector leads to a complete reversion of liver cirrhosis in rats

    PLoS ONE, Vol. 11, Núm. 9

  3. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

2014

  1. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation

    Journal of Hepatology, Vol. 60, Núm. 5, pp. 1017-1025

  2. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

2013

  1. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  2. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087

  3. Safety and liver transduction efficacy of raav5-cohpbgd in nonhuman primates: A potential therapy for acute intermittent porphyria

    Human Gene Therapy, Vol. 24, Núm. 12, pp. 1007-1017

2012

  1. AAV vectors transduce hepatocytes in vivo as efficiently in cirrhotic as in healthy rat livers

    Gene Therapy, Vol. 19, Núm. 4, pp. 411-417

2011

  1. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages

    Annals of Surgical Oncology, Vol. 18, Núm. 7, pp. 1964-1971

  2. Transarterial therapies for hepatocellular carcinoma

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 7, pp. 1057-1073

2010

  1. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 77, Núm. 5, pp. 1441-1448

  2. Insulin-like growth factor i gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats

    Hepatology, Vol. 51, Núm. 3, pp. 912-921